Effects of dexmedetomidine on acute kidney injury after cardiopulmonary bypass in paediatric patients with congenital heart disease

Effects of dexmedetomidine on acute kidney injury after cardiopulmonary bypass in paediatric patients with congenital heart disease: a single-centre, placebo-controlled, randomised controlled trial

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000031446

Enrollment

Unknown

Registered

2020-04-01

Start date

2020-04-10

Completion date

Unknown

Last updated

2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Congenital heart disease

Interventions

experimental group:Intraoperative infusion of dexmedetomidine

control group:Intraoperative infusion of normal saline

Eligibility

Sex/Gender

All

Age

No minimum to 3 Years

Inclusion criteria

Inclusion criteria: 1. ASA 1-3 grade; 2. Aged 1 month-3 years; 3. Patients who will undergo radical operation of congenital heart disease under cardiopulmonary bypass.

Exclusion criteria

Exclusion criteria: 1. Patients with preoperative SCR over 7 mg / L; 2. Patients with cyanotic heart disease; 3. Patients with arrhythmia, severe left ventricular dysfunction (left ventricular ejection fraction < 50%) and right heart failure; 4. Patients who used cardiotonic drugs and vasoactive drugs before operation; 5. Patients with respiratory diseases.

Design outcomes

Primary

Measure	Time frame
incidence of postoperative AKI;	—

Secondary

Measure	Time frame
Postoperative mechanical ventilation duration;ICU stay time after surgery;Postoperative hospital stay;	—

Countries

China

Contacts

Public ContactZhou Dandan

Northwest Women's and Children's Hospital

zdd820326@163.com+86 17791303680

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026